# A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Source: https://onco.cc/trials/nct05410145/  
OnCo record `nct05410145` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.

## Summary

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05410145 by D3 Bio (Wuxi) Co., Ltd, with 442 participants planned, started 2022-08-03 and due to reach its primary completion in 2027-04. Interventions recorded: D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05410145
- Phase: 1/2
- Setting: A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- Sponsor: D3 Bio (Wuxi) Co., Ltd
- Enrolled: 442

## Sources

- ClinicalTrials.gov NCT05410145: https://clinicaltrials.gov/study/NCT05410145

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05410145.json